<DOC>
	<DOCNO>NCT02963714</DOCNO>
	<brief_summary>Intramuscular injection 40 μg hepatitis B vaccine standard three-dose schedule four-dose schedule recommend hemodialysis patient . However , seroconversion rate inadequate persistence immunity remain challenge . This randomize , control trial . The study evaluate immunogenicity , immune persistence , safety 20 µg 60 µg recombinant hepatitis B vaccine three injection month 0 , 1 , 6 hemodialysis patient .</brief_summary>
	<brief_title>Immunogenicity Hepatitis B Vaccination Hemodialysis Patients</brief_title>
	<detailed_description>Participants randomize ratio 1:1 20 µg recombinant hepatitis B vaccine group 60µg recombinant hepatitis B vaccine group.The 20 µg group receive three intramuscular injection 20 µg recombinant hepatitis B vaccine , 60 µg group receive three intramuscular injection 60 µg dose month 0 , 1 6 , respectively . HBsAg anti-HBs test study period . Adverse reaction record vaccination .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Having endstage renal disease ( ESRD ) maintenance hemodialysis Aged 18 70 year enrollment Serologically negative hepatitis B surface antigen ( HBsAg ) hepatitis B surface antibody ( antiHBs ) enrollment Willing adhere study protocol Being pregnant Acute cytolysis last three month enrollment Any vaccination month precede enrollment Intolerance allergy component vaccine Ongoing opportunistic infection Hepatitis C virus infection Hematological disorder Cancer Unexplained fever week enrollment Immunosuppressive immunomodulating treatment last six month Renal transplantation upcoming renal transplantation Liver disease Other immunocompromised condition relate ESRD An expected survival &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B , Vaccine</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>